noscript

News and Announcements

Proteomics Secures First Commercialisation Deal for PromarkerD

  • Published August 18, 2016 2:45PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

18th August 2016, ASX Announcement

Life sciences company Proteomics International Laboratories  (ASX: PIQ) (PILL) has signed an exclusive license for its PromarkerD assay for the diagnosis of diabetic kidney disease in the Dominican Republic in Central America.

Highlights:

  • Diabetic kidney disease test to be commercialised in the Dominican Republic in a deal worth in excess of USD 1.5 million.
  • The agreement marks the first international licensing deal for the PromarkerD assay.
  • Manufacturing will occur in US Territory of Puerto Rico and the deal paves the way for other markets including the United States, China and Japan.

The licence granted to Omics Global Solution (Omics) for the Dominican Republic for the PromarkerD assay will provide significant economic benefit to PILL. Although the Dominican Republic has only 10.6 million people, the net present value of financial terms in excess of USD 1.5M for the first nine years of the agreement.

To view the full announcement, please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now